Arcturus Therapeutics Holdings Inc. (ARCT) Q1 FY26 Earnings Call

Rare-disease milestones are advancing with runway beyond Q2 2028, but revenue fell as CSL collaboration declines.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Call date2026-05-07
Length44 minutes
EPS$-0.95
EPS consensus$-1.14
Revenue$2.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All ARCT earnings ยท Back to ARCT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.